Reconsider Capping Price Of N-95 Masks Urges Bombay HC As Centre Contends Masks Already Sold At 47% Reduced Price
Live LawThe Bombay High Court on Tuesday questioned the Centre and National Pharmaceutical Pricing Authority regarding the cap on price of N-95 masks considering the Drug Price Control Order which states that the government will have to ensure that prices are not increased more than 10% of prices prevailing in preceding 12 months. Division bench of Chief Justice Dipankar Datta and Justice SS Shinde urged the NPPA to reconsider capping the price of N-95 masks in public interest and ensuring that hoarding as well as black marketing of these masks does not take place. Court was hearing a PIL filed by journalist Sucheta Dalal and activist Anjali Damania seeking directions against hoarding, black marketing of N-95 masks in the State. Clause 20 of the DPCO states that the maximum retail prices of all the medical devices would be monitored by the government to ensure that no manufacturer or importer increases the MRP of a drug more than 10% of MRP during preceding 12 months and where the increase is beyond 10% of maximum retail price, it shall reduce the same to the level of 10% of maximum retail price for next 12 months.